Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)

Completed · Phase 3 · Has a placebo group

Conditions studied: Diabetic Retinopathy

In brief

Diabetic retinopathy (DR) is an eye disease that can occur in people with diabetes and can cause poor vision or blindness. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study is examining the effect of various treatments on cardiovascular disease in people with diabetes. This current study will examine the effects of the ACCORD treatments on the progression of DR in people participating in the ACCORD study.

Key facts

Study ID

NCT00542178

Run by

National Heart, Lung, and Blood Institute (NHLBI)

People needed

3472

Starts

2003-10-01

Expected to finish

2009-12-01

Last updated by the study team

2018-07-24

Who can join

Age: 40 and older, up to 79. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participating in the ACCORD study

You may not qualify if…

• Has had laser photocoagulation for DR
• Has had vitrectomy surgery for DR

Where it is running

• The Berman Center for Clinical Research — Minneapolis, Minnesota, United States
• Columbia University — New York, New York, United States
• Wake Forest University Health Sciences — Winston-Salem, North Carolina, United States
• Case Western Reserve University — Cleveland, Ohio, United States
• Veterans Affairs — Memphis, Tennessee, United States
• University of Washington — Seattle, Washington, United States
• McMaster University — Hamilton, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.